MX2007011908A - Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas. - Google Patents
Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas.Info
- Publication number
- MX2007011908A MX2007011908A MX2007011908A MX2007011908A MX2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A MX 2007011908 A MX2007011908 A MX 2007011908A
- Authority
- MX
- Mexico
- Prior art keywords
- calcium
- barium
- magnesium
- active substances
- hydrated
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000017497 prostate disease Diseases 0.000 title 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 abstract 4
- 239000000919 ceramic Substances 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 abstract 2
- 239000001175 calcium sulphate Substances 0.000 abstract 2
- 235000011132 calcium sulphate Nutrition 0.000 abstract 2
- 230000000887 hydrating effect Effects 0.000 abstract 2
- 210000002307 prostate Anatomy 0.000 abstract 2
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 abstract 1
- 229910001632 barium fluoride Inorganic materials 0.000 abstract 1
- 229910052916 barium silicate Inorganic materials 0.000 abstract 1
- HMOQPOVBDRFNIU-UHFFFAOYSA-N barium(2+);dioxido(oxo)silane Chemical compound [Ba+2].[O-][Si]([O-])=O HMOQPOVBDRFNIU-UHFFFAOYSA-N 0.000 abstract 1
- WAKZZMMCDILMEF-UHFFFAOYSA-H barium(2+);diphosphate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O WAKZZMMCDILMEF-UHFFFAOYSA-H 0.000 abstract 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 abstract 1
- 229910001634 calcium fluoride Inorganic materials 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
- 235000011010 calcium phosphates Nutrition 0.000 abstract 1
- 239000000378 calcium silicate Substances 0.000 abstract 1
- 229910052918 calcium silicate Inorganic materials 0.000 abstract 1
- 235000012241 calcium silicate Nutrition 0.000 abstract 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 abstract 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 abstract 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 abstract 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 abstract 1
- 239000004137 magnesium phosphate Substances 0.000 abstract 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 abstract 1
- 229960002261 magnesium phosphate Drugs 0.000 abstract 1
- 235000010994 magnesium phosphates Nutrition 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 1
- 235000019792 magnesium silicate Nutrition 0.000 abstract 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract 1
- 235000019341 magnesium sulphate Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe un metodo para tratar enfermedades relacionadas con la prostata en un sujeto, el metodo comprende: i) opcionalmente administrar al sujeto una dosis de refuerzo inicial de una o mas sustancias activas o precursores, y ii) administrar localmente en la prostata una composicion farmaceutica de liberacion controlada que comprende una o mas sustancias activas en un portador ceramico biodegradable. El material ceramico hidratante biodegradable se puede seleccionar del grupo que consiste de las formas no hidratada o hidratada de sulfato de calcio, fosfato de calcio, carbonato de calcio, fluoruro de calcio, silicato de calcio, sulfato de magnesio, fosfato de magnesio, carbonato de magnesio, fluoruro de magnesio, silicato de magnesio, sulfato de bario, fosfato de bario, carbonato de bario, fluoruro de bario, silicato de bario o mezclas de los mismos. En una modalidad especifica, el material ceramico hidratante biodegradable es sulfato de calcio no hidratado o hidratado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500452 | 2005-03-31 | ||
| PCT/EP2006/003194 WO2006103112A2 (en) | 2005-03-31 | 2006-03-31 | Method for treating prostate diseases based on local delivery of active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007011908A true MX2007011908A (es) | 2008-02-07 |
Family
ID=35044589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007011908A MX2007011908A (es) | 2005-03-31 | 2006-03-31 | Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8936809B2 (es) |
| EP (1) | EP1865924B1 (es) |
| JP (2) | JP5635231B2 (es) |
| KR (2) | KR101380402B1 (es) |
| CN (1) | CN101160116B (es) |
| AU (1) | AU2006228675B2 (es) |
| CA (1) | CA2602776C (es) |
| DK (1) | DK1865924T3 (es) |
| ES (1) | ES2557988T3 (es) |
| HU (1) | HUE026158T2 (es) |
| IL (1) | IL185690A0 (es) |
| MX (1) | MX2007011908A (es) |
| NO (1) | NO338679B1 (es) |
| PL (1) | PL1865924T3 (es) |
| RU (1) | RU2404747C2 (es) |
| WO (1) | WO2006103112A2 (es) |
| ZA (1) | ZA200708066B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1865924B1 (en) * | 2005-03-31 | 2015-12-09 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
| ES2545962T3 (es) * | 2008-11-27 | 2015-09-17 | Lidds Ab | Uso de carboximetilcelulosa para controlar la capacidad de eyección y el tiempo de solidificación de composiciones que comprenden una o más cerámicas biorreabsorbibles |
| AU2012240131B2 (en) * | 2011-04-05 | 2017-07-20 | Edge Therapeutics | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
| RU2519407C2 (ru) * | 2011-09-21 | 2014-06-10 | Виктор Павлович Горелов | Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты |
| GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
| GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
| EP3597176A1 (en) | 2014-08-19 | 2020-01-22 | The Regents Of The University Of California | Implants for localized drug delivery and methods of use thereof |
| CN107683174B (zh) | 2015-06-04 | 2021-02-19 | 克里蒂泰克公司 | 喷嘴组件及其使用方法 |
| CN109475492B (zh) | 2016-04-04 | 2022-04-29 | 克里蒂泰克公司 | 实体肿瘤治疗方法 |
| AU2018279634A1 (en) | 2017-06-09 | 2019-10-31 | Crititech, Inc. | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| AU2018284247B2 (en) | 2017-06-14 | 2020-04-30 | Crititech Inc. | Methods for treating lung disorders |
| JP7792750B2 (ja) | 2017-10-03 | 2025-12-26 | クリティテック・インコーポレイテッド | 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達 |
| WO2020061291A1 (en) * | 2018-09-20 | 2020-03-26 | Biovena Science, Llc | Flutamide microsphere-based arterial embolization for treating prostate disorders |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| US11173291B2 (en) * | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) * | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11338119B2 (en) * | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| JP7665645B2 (ja) | 2020-03-20 | 2025-04-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 局所的な薬物送達のための移植可能な薬物送達デバイス |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
| US11974979B2 (en) | 2022-01-29 | 2024-05-07 | Resurge Therapeutics, Inc. | Treatments for benign prostatic hyperplasia |
| JP2025505974A (ja) * | 2022-01-29 | 2025-03-05 | リサージ セラピューティクス，インコーポレイテッド | 良性前立腺過形成治療システム |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
| US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
| US5795330A (en) * | 1996-10-10 | 1998-08-18 | Etex Corporation | Mixing device |
| ATE381314T1 (de) * | 1996-10-16 | 2008-01-15 | Etex Corp | Biokeramische zusammensetzung |
| US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| US5972384A (en) * | 1997-10-01 | 1999-10-26 | University Of Maryland, Baltimore | Use of biologically active glass as a drug delivery system |
| CA2378486A1 (en) | 1999-08-05 | 2001-02-15 | Takashi Kurasawa | Osteogenesis promoter sustained-release paste |
| US6497901B1 (en) * | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
| US6645974B2 (en) * | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| US20030147936A1 (en) * | 2002-02-07 | 2003-08-07 | Velayudhan Sahadevan | Prostatic hormonal implants treatment of prostate cancer |
| JP2006523681A (ja) * | 2003-03-24 | 2006-10-19 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | Ｄｎａ−ｐｋ阻害剤としてのキサントン、チオキサントンおよびアクリジノン |
| GB0307082D0 (en) * | 2003-03-27 | 2003-04-30 | Gyne Ideas Ltd | Drug delivery device and method |
| CN102697737B (zh) * | 2003-04-03 | 2014-03-19 | 杰西.L.-S.奥 | 负载肿瘤靶向药物的颗粒 |
| US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
| WO2005039537A1 (en) * | 2003-10-22 | 2005-05-06 | Lidds Ab | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| EP1865924B1 (en) * | 2005-03-31 | 2015-12-09 | Lidds Ab | Method for treating prostate diseases based on local delivery of active substances |
-
2006
- 2006-03-31 EP EP06724133.1A patent/EP1865924B1/en not_active Expired - Lifetime
- 2006-03-31 AU AU2006228675A patent/AU2006228675B2/en not_active Ceased
- 2006-03-31 RU RU2007140243/14A patent/RU2404747C2/ru active
- 2006-03-31 DK DK06724133.1T patent/DK1865924T3/en active
- 2006-03-31 MX MX2007011908A patent/MX2007011908A/es active IP Right Grant
- 2006-03-31 JP JP2008503447A patent/JP5635231B2/ja not_active Expired - Fee Related
- 2006-03-31 ES ES06724133.1T patent/ES2557988T3/es not_active Expired - Lifetime
- 2006-03-31 WO PCT/EP2006/003194 patent/WO2006103112A2/en not_active Ceased
- 2006-03-31 KR KR1020077022037A patent/KR101380402B1/ko not_active Expired - Fee Related
- 2006-03-31 HU HUE06724133A patent/HUE026158T2/en unknown
- 2006-03-31 KR KR1020137034233A patent/KR20140014294A/ko not_active Ceased
- 2006-03-31 CN CN2006800100200A patent/CN101160116B/zh not_active Expired - Fee Related
- 2006-03-31 CA CA2602776A patent/CA2602776C/en not_active Expired - Lifetime
- 2006-03-31 PL PL06724133T patent/PL1865924T3/pl unknown
- 2006-03-31 US US11/910,162 patent/US8936809B2/en active Active
-
2007
- 2007-09-03 IL IL185690A patent/IL185690A0/en active IP Right Grant
- 2007-09-19 ZA ZA2007/08066A patent/ZA200708066B/en unknown
- 2007-10-30 NO NO20075490A patent/NO338679B1/no unknown
-
2012
- 2012-11-27 JP JP2012258603A patent/JP2013067639A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL1865924T3 (pl) | 2016-06-30 |
| CA2602776C (en) | 2013-10-22 |
| DK1865924T3 (en) | 2016-02-29 |
| US8936809B2 (en) | 2015-01-20 |
| KR20080002776A (ko) | 2008-01-04 |
| NO338679B1 (no) | 2016-09-26 |
| WO2006103112A2 (en) | 2006-10-05 |
| AU2006228675B2 (en) | 2012-05-17 |
| CN101160116A (zh) | 2008-04-09 |
| KR101380402B1 (ko) | 2014-04-02 |
| WO2006103112A3 (en) | 2006-12-21 |
| JP5635231B2 (ja) | 2014-12-03 |
| IL185690A0 (en) | 2008-01-06 |
| KR20140014294A (ko) | 2014-02-05 |
| RU2007140243A (ru) | 2009-05-10 |
| JP2008534546A (ja) | 2008-08-28 |
| EP1865924B1 (en) | 2015-12-09 |
| NO20075490L (no) | 2008-01-02 |
| JP2013067639A (ja) | 2013-04-18 |
| CA2602776A1 (en) | 2006-10-05 |
| RU2404747C2 (ru) | 2010-11-27 |
| ZA200708066B (en) | 2016-07-27 |
| ES2557988T3 (es) | 2016-02-01 |
| CN101160116B (zh) | 2011-12-07 |
| US20080286205A1 (en) | 2008-11-20 |
| EP1865924A2 (en) | 2007-12-19 |
| AU2006228675A1 (en) | 2006-10-05 |
| HUE026158T2 (en) | 2016-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007011908A (es) | Metodo basado en el suministro local de sustancias activas para tratar enfermedades prostaticas. | |
| EP2059205A4 (en) | METHOD FOR PRODUCING A SOLID FIRM FOR TREATMENT OF INJURED TISSUE | |
| MX344241B (es) | Sistema terapeutico transdermico para administrar la sustancia activa buprenorfina. | |
| IL194812A0 (en) | Integrated wound dressing system | |
| MX341883B (es) | Composicion farmaceutica para el tratamiento y prevencion de canceres. | |
| NZ602571A (en) | Micrornas that regulate muscle cell proliferation and differentiation | |
| WO2007133941A3 (en) | Therapeutic agent carrier | |
| IL182262A0 (en) | Self-fixating scaffolds | |
| CR10349A (es) | Tabletas de paracetamol de liberacion rapida | |
| WO2007127163A3 (en) | Cns-tumor treatment method and composition | |
| SG178975A1 (en) | Indenone derivative and pharmaceutical composition comprising same | |
| WO2005007072A3 (en) | Methods and pharmaceutical compositions for healing wounds | |
| NZ582556A (en) | Pharmaceutical composition for treating wounds and related methods | |
| TW200602030A (en) | Use of loteprednol etabonate for the treatment of dry eye | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2005016265A3 (en) | Method for promoting bone growth | |
| GB2446341A (en) | Method and system for transdermal drug delivery | |
| WO2006050368A3 (en) | Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use | |
| WO2011024168A3 (en) | Sustained release delivery systems for the prevention and treatment of head and neck cancers | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| SI1603584T1 (sl) | Aplidin za zdravljenje multiple mieloma | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| WO2007149543A3 (en) | Scar treatment using protein phosphatase inhibitors | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| WO2006002326A3 (en) | Methods for treatment of wounds using time release compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |